Integer (ITGR) 10-Q 13 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Apr. 04, 2014	13-May-14
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'GREATBATCH, INC.	'
Entity Central Index Key	'0001114483	'
Document Type	'10-Q	'
Document Period End Date	4-Apr-14	'
Amendment Flag	'false	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Current Fiscal Year End Date	'--01-02	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	24,880,319

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$38,325	$35,465
Accounts receivable, net of allowance for doubtful accounts of $2.0 million in 2014 and 2013	117,221	113,679
Inventories	118,083	118,358
Refundable income taxes	0	2,306
Deferred income taxes	5,967	6,008
Prepaid expenses and other current assets	5,165	6,717
Total current assets	284,761	282,533
Property, plant and equipment, net	145,186	145,773
Amortizing intangible assets, net	72,922	76,122
Indefinite-lived intangible assets	20,288	20,288
Goodwill	347,251	346,656
Deferred income taxes	2,949	2,933
Other assets	17,020	16,398
Total assets	890,377	890,703
Current liabilities:	'	'
Accounts payable	43,122	46,508
Income taxes payable	1,889	0
Deferred income taxes	619	613
Accrued expenses	24,366	44,681
Total current liabilities	69,996	91,802
Long-term debt	195,000	197,500
Deferred income taxes	51,440	52,012
Other long-term liabilities	7,119	7,334
Total liabilities	323,555	348,648
Stockholders’ equity:	'	'
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding in 2014 or 2013	0	0
Common stock, $0.001 par value, authorized 100,000,000 shares; 24,836,970 shares issued and 24,820,665 shares outstanding in 2014; 24,459,153 shares issued and 24,422,555 shares outstanding in 2013	25	24
Additional paid-in capital	352,988	344,915
Treasury stock, at cost, 16,305 shares in 2014 and 36,598 shares in 2013	-720	-1,232
Retained earnings	198,912	183,990
Accumulated other comprehensive income	15,617	14,358
Total stockholders’ equity	566,822	542,055
Total liabilities and stockholders’ equity	$890,377	$890,703

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Millions, except Share data, unless otherwise specified
Current assets:	'	'
Allowance for doubtful accounts	$2	$2
Stockholders’ equity:	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	24,836,970	24,459,153
Common stock, shares outstanding	24,820,665	24,422,555
Treasury stock, shares	16,305	36,598

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Income Statement [Abstract]	'	'
Sales	$174,281	$148,265
Cost of sales	116,685	99,516
Gross profit	57,596	48,749
Operating expenses:	'	'
Selling, general and administrative expenses	21,755	20,092
Research, development and engineering costs, net	13,531	11,080
Other operating (income) expenses, net	-214	3,238
Total operating expenses	35,072	34,410
Operating income	22,524	14,339
Interest expense	1,084	6,988
Other (income) expense, net	-621	285
Income before provision for income taxes	22,061	7,066
Provision for income taxes	7,139	1,403
Net income	14,922	5,663
Earnings per share:	'	'
Basic	$0.61	$0.24
Diluted	$0.58	$0.23
Weighted average shares outstanding:	'	'
Basic	24,614	23,750
Diluted	25,694	24,415
Comprehensive Income	'	'
Net income	14,922	5,663
Foreign currency translation gain (loss)	1,182	-3,063
Net change in cash flow hedges, net of tax	77	269
Defined benefit plan liability adjustment, net of tax	0	597
Other comprehensive income (loss)	1,259	-2,197
Comprehensive income	$16,181	$3,466

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Cash flows from operating activities:	'	'
Net income	$14,922	$5,663
Adjustments to reconcile net income to net cash provided by (used in) operating activities:	'	'
Depreciation and amortization	9,252	8,764
Debt related amortization included in interest expense	192	5,759
Stock-based compensation	3,177	2,431
Other non-cash gains	-3,684	-930
Deferred income taxes	-590	-29,212
Changes in operating assets and liabilities:	'	'
Accounts receivable	-3,392	-3,897
Inventories	518	-12,073
Prepaid expenses and other current assets	1,564	80
Accounts payable	-2,663	-512
Accrued expenses	-16,733	-13,920
Income taxes payable	4,438	30,252
Net cash provided by (used in) operating activities	7,001	-7,595
Cash flows from investing activities:	'	'
Acquisition of property, plant and equipment	-5,974	-6,745
Proceeds from sale of orthopaedic product lines (Note 8)	2,531	1,768
Purchase of cost and equity method investments	0	-810
Other investing activities	0	8
Net cash used in investing activities	-3,443	-5,779
Cash flows from financing activities:	'	'
Principal payments of long-term debt	-2,500	-205,782
Proceeds from issuance of long-term debt	0	208,000
Issuance of common stock	3,445	1,185
Other financing activities	-1,608	-81
Net cash provided by (used in) financing activities	-663	3,322
Effect of foreign currency exchange rates on cash and cash equivalents	-35	-88
Net increase (decrease) in cash and cash equivalents	2,860	-10,140
Cash and cash equivalents, beginning of period	35,465	20,284
Cash and cash equivalents, end of period	$38,325	$10,144

Condensed_Consolidated_Stateme2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
In Thousands, unless otherwise specified
Balance at Jan. 03, 2014	$542,055	$24	$344,915	($1,232)	$183,990	$14,358
Balance, shares at Jan. 03, 2014	'	24,459	'	-37	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'
Stock-based compensation	2,161	'	2,161	'	'	'
Net shares issued under stock incentive plans, shares	'	378	'	-74	'	'
Net shares issued under stock incentive plans	2,084	1	5,786	-3,703	'	'
Shares contributed to 401(k), shares	'	'	'	95	'	'
Shares contributed to 401(k)	4,341	'	126	4,215	'	'
Net income	14,922	'	'	'	14,922	'
Total other comprehensive income (loss)	1,259	'	'	'	'	1,259
Balance at Apr. 04, 2014	$566,822	$25	$352,988	($720)	$198,912	$15,617
Balance, shares at Apr. 04, 2014	'	24,837	'	-16	'	'

Basis_of_Presentation

Basis of Presentation	3 Months Ended
	Apr. 04, 2014
Accounting Policies [Abstract]	'
BASIS OF PRESENTATION	'
	BASIS OF PRESENTATION
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The January 3, 2014 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 3, 2014. The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. The first quarter of 2014 and 2013 each contained 13 weeks, and ended on April 4, and March 29, respectively.

Supplemental_Cash_Flow_Informa

Supplemental Cash Flow Information	3 Months Ended
	Apr. 04, 2014
Supplemental Cash Flow Information [Abstract]	'
SUPPLEMENTAL CASH FLOW INFORMATION	'
	SUPPLEMENTAL CASH FLOW INFORMATION
		Three Months Ended
	(in thousands)	April 4, 2014		March 29, 2013
	Noncash investing and financing activities:
	Common stock contributed to 401(k) Plan	$	4,341	$	2,477
	Property, plant and equipment purchases included in accounts payable	1,180		1,219
	Cash paid during the period for:
	Interest	$	953	$	1,556
	Income taxes	544		494

Inventories

Inventories	3 Months Ended
	Apr. 04, 2014
Inventory Disclosure [Abstract]	'
INVENTORIES	'
	INVENTORIES
	Inventories are comprised of the following (in thousands):
		As of
		4-Apr-14		3-Jan-14
	Raw materials	$	66,539	$	67,939
	Work-in-process	36,779		36,670
	Finished goods	14,765		13,749
	Total	$	118,083	$	118,358

Intangible_Assets

Intangible Assets	3 Months Ended
	Apr. 04, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS	'
	INTANGIBLE ASSETS
	Amortizing intangible assets are comprised of the following (in thousands):
		Gross		Accumulated			Foreign		Net
		Carrying		Amortization			Currency		Carrying
		Amount					Translation		Amount
	At April 4, 2014
	Technology and patents	$	97,376	$	(70,708	)	$	1,993	$	28,661
	Customer lists	68,257		(26,337		)	1,552		43,472
	Other	4,434		(4,532		)	887		789
	Total amortizing intangible assets	$	170,067	$	(101,577	)	$	4,432	$	72,922
	At January 3, 2014
	Technology and patents	$	97,376	$	(69,026	)	$	1,980	$	30,330
	Customer lists	68,257		(24,671		)	1,367		44,953
	Other	4,434		(4,399		)	804		839
	Total amortizing intangible assets	$	170,067	$	(98,096	)	$	4,151	$	76,122
	Aggregate intangible asset amortization expense is comprised of the following (in thousands):
		Three Months Ended
		4-Apr-14		29-Mar-13
	Cost of sales	$	1,563	$	1,780
	Selling, general and administrative expenses	1,717		1,452
	Research, development and engineering costs, net	201		136
	Total intangible asset amortization expense	$	3,481	$	3,368
	Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands):
		Estimated
		Amortization
		Expense
	Remainder of 2014	$	10,238
	2015	12,668
	2016	10,373
	2017	9,251
	2018	6,962
	Thereafter	23,430
	Total estimated amortization expense	$	72,922
	Indefinite-lived intangible assets are comprised of the following (in thousands):
		Trademarks
		and
		Tradenames
	At January 3, 2014	$	20,288
	At April 4, 2014	$	20,288
	The change in goodwill is as follows (in thousands):
		Greatbatch Medical		QiG			Total
	At January 3, 2014	$	304,856	$	41,800		$	346,656
	Foreign currency translation	595		—			595
	At April 4, 2014	$	305,451	$	41,800		$	347,251

Debt

Debt	3 Months Ended
	Apr. 04, 2014
Debt Disclosure [Abstract]	'
DEBT	'
	DEBT
	Long-term debt is comprised of the following (in thousands):
		As of
		4-Apr-14				3-Jan-14
	Revolving line of credit	$	—			$	—
	Variable rate term loan	195,000				197,500
	Total long-term debt	$	195,000			$	197,500
	Credit Facility – In September 2013, the Company amended and extended its credit facility (the “Credit Facility”). The new Credit Facility provides a $300 million revolving credit facility (the “Revolving Credit Facility”), a $200 million term loan (the “Term Loan”), a $15 million letter of credit subfacility, and a $15 million swingline subfacility. The Credit Facility can be increased by $200 million upon the Company’s request and approval by the lenders. The Revolving Credit Facility has a maturity date of September 20, 2018, which may be extended to September 20, 2019 upon notice by the Company and subject to certain conditions. The principal of the Term Loan is payable in quarterly installments as specified in the Credit Facility until its maturity date of September 20, 2019, when the unpaid balance is due in full.
	The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories. Interest rates on the Revolving Credit Facility and Term Loan are, at the Company’s option either at: (i) the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company’s total leverage ratio or (ii) the applicable LIBOR rate plus the applicable margin, which ranges between 1.375% and 2.75%, based on the Company’s total leverage ratio. Loans under the swingline subfacility will bear interest at the prime rate plus the applicable margin, which ranges between 0.0% and 0.75%, based on the Company’s total leverage ratio. The Company is also required to pay a commitment fee, which varies between 0.175% and 0.25% depending on the Company’s total leverage ratio.
	The Credit Facility contains limitations on the incurrence of indebtedness, liens and licensing of intellectual property, investments and certain payments. The Credit Facility permits the Company to engage in the following activities up to an aggregate amount of $300 million: 1) engage in permitted acquisitions in the aggregate not to exceed $250 million; 2) make other investments in the aggregate not to exceed $100 million; 3) make stock repurchases and declare dividends not to exceed $150 million in the aggregate; and 4) make investments in foreign subsidiaries not to exceed $20 million in the aggregate. At any time that the total leverage ratio of the Company for the two most recently ended fiscal quarters is less than 2.75 to 1.0, the Company may make an election to reset each of the amounts specified above. Additionally, these limitations can be waived upon the Company’s request and approval of a majority of the lenders. As of April 4, 2014, the Company had available to it 100% of the above limits except for the aggregate limit and other investments limit which are now $298 million and $98 million, respectively.
	The Credit Facility requires the Company to maintain a rolling four quarter ratio of adjusted EBITDA to interest expense of at least 3.0 to 1.0, and a total leverage ratio of not greater than 4.5 to 1.0 and a total leverage ratio not greater than 4.25 to 1.0 after January 2, 2016. The calculation of adjusted EBITDA and total leverage ratio excludes non-cash charges, extraordinary, unusual, or non-recurring expenses or losses, non-cash stock-based compensation, and non-recurring expenses or charges incurred in connection with permitted acquisitions. As of April 4, 2014, the Company was in compliance with all covenants under the Credit Facility.
	The Credit Facility contains customary events of default. Upon the occurrence and during the continuance of an event of default, a majority of the lenders may declare the outstanding advances and all other obligations under the Credit Facility immediately due and payable.
	As of April 4, 2014, the weighted average interest rate on borrowings under the Credit Facility, which does not take into account the impact of the Company’s interest rate swap, was 1.57%. As of April 4, 2014, the Company had $300 million of borrowing capacity available under the Credit Facility. This borrowing capacity may vary from period to period based upon the debt and EBITDA levels of the Company, which impacts the covenant calculations described above.
	Interest Rate Swap – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on the outstanding borrowings on the Credit Facility. The variable rate received on the interest rate swaps and the variable rate paid on the debt have the same rate of interest, excluding the credit spread, and resets and pays interest on the same date. During 2012, the Company entered into a three-year $150 million interest rate swap, which amortizes $50 million per year. This swap was entered into in order to hedge against potential changes in cash flows on the outstanding Credit Facility borrowings, which are also indexed to the one-month LIBOR rate. This swap is being accounted for as a cash flow hedge. Information regarding the Company’s outstanding interest rate swap as of April 4, 2014 is as follows (dollars in thousands):
	Instrument	Type of		Notional				Start	End	Pay		Current		Fair			Balance
		Hedge		Amount				Date	Date	Fixed		Receive		Value			Sheet Location
										Rate		Floating		April 4, 2014
												Rate
	Interest rate swap	Cash flow		$	100,000			13-Feb	16-Feb	0.573	%	0.157	%	$	(330	)	Other Long-Term Liabilities
	The estimated fair value of the interest rate swap agreement represents the amount the Company expects to receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swap during the three months ended April 4, 2014 was considered ineffective. The amount recorded as Interest Expense during the three months ended April 4, 2014 and March 29, 2013 related to the Company’s interest rate swap was $0.1 million and $0.06 million, respectively.
	Convertible Subordinated Notes – In March 2007, the Company issued $197.8 million of convertible subordinated notes (“CSN”) at a 5% discount. CSN accrued interest at 2.25% per annum. The effective interest rate of CSN, which took into consideration the amortization of the discount and deferred fees related to the issuance of these notes, was 8.5%. On February 20, 2013, the Company redeemed all outstanding CSN.
	The contractual interest and discount amortization for CSN were as follows (in thousands):
		Three months ended
		4-Apr-14				29-Mar-13
	Contractual interest	$	—			$	634
	Discount amortization	—				5,368
	The expected future minimum principal payments under the Term Loan as of April 4, 2014 are as follows (in thousands):
	Remainder of 2014	$	7,500
	2015	11,250
	2016	16,250
	2017	20,000
	2018	20,000
	Thereafter	120,000
	Total	$	195,000
	The Company has the ability and intent to use availability under the Revolving Credit Facility to fund principal payments on the Term Loan.
	Deferred Financing Fees - The change in deferred financing fees is as follows (in thousands):
	At January 3, 2014	$	3,860
	Amortization during the period	(192		)
	At April 4, 2014	$	3,668

Defined_Benefit_Plans

Defined Benefit Plans	3 Months Ended
	Apr. 04, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
DEFINED BENEFIT PLANS	'
	DEFINED BENEFIT PLANS
	The Company is required to provide its employees located in Switzerland, Mexico and France certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit plan provided to employees located in Switzerland is a funded contributory plan while the plans that provide benefits to employees located in Mexico and France are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees.
	During 2012, the Company transferred most major functions performed at its facilities in Switzerland into other existing facilities. As a result, the Company curtailed its defined benefit plan provided to employees at those Swiss facilities and recognized a curtailment gain during 2013. In accordance with ASC 715, this gain was recognized in Other Operating Expenses, Net as the related employees were terminated.
	The change in net defined benefit plan liability is as follows (in thousands):
	At January 3, 2014	$	1,691
	Net defined benefit cost	77
	Benefit payments	(131		)
	Foreign currency translation	14
	At April 4, 2014	$	1,651
	Net defined benefit cost (income) is comprised of the following (in thousands):
		Three Months Ended
		4-Apr-14			29-Mar-13
	Service cost	$	52		$	82
	Interest cost	19			63
	Curtailment gain	—			(1,150		)
	Amortization of net loss	6			—
	Net defined benefit cost (income)	$	77		$	(1,005	)

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Apr. 04, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	STOCK-BASED COMPENSATION
	The components and classification of stock-based compensation expense were as follows (in thousands):
		Three Months Ended
		4-Apr-14				29-Mar-13
	Stock options	$	604			$	705
	Restricted stock and units	1,557				1,463
	401(k) Plan stock contribution	1,016				263
	Total stock-based compensation expense	$	3,177			$	2,431
	Cost of sales	$	911			$	422
	Selling, general and administrative expenses	1,923				1,867
	Research, development and engineering costs, net	343				142
	Total stock-based compensation expense	$	3,177			$	2,431
	The weighted average fair value and assumptions used to value options granted are as follows:
		Three Months Ended
		4-Apr-14				29-Mar-13
	Weighted average fair value	$	16.41			$	8.38
	Risk-free interest rate	1.73		%		0.73		%
	Expected volatility	39		%		39		%
	Expected life (in years)	5				5
	Expected dividend yield	—		%		—		%
	The following table summarizes time-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Time-Vested			Average				Average	Intrinsic
		Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 3, 2014	1,616,409			$	22.92
	Granted	181,553			43.78
	Exercised	(123,388	)		23.39
	Forfeited or expired	(19,216	)		26.43
	Outstanding at April 4, 2014	1,655,358			25.14				6.7	$	32.6
	Exercisable at April 4, 2014	1,219,492			22.9				5.9	$	26.8
	The following table summarizes performance-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Performance-			Average				Average	Intrinsic
		Vested Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 3, 2014	177,261			$	23.27
	Exercised	(24,335	)		22.96
	Outstanding at April 4, 2014	152,926			23.32				3.3	$	3.3
	Exercisable at April 4, 2014	152,926			23.32				3.3	$	3.3
	The following table summarizes time-vested restricted stock and unit activity:
		Time-Vested			Weighted
		Activity			Average
					Fair Value
	Nonvested at January 3, 2014	67,575			$	26.37
	Granted	34,721			43.99
	Vested	(4,874	)		43.8
	Forfeited	(4,113	)		31.68
	Nonvested at April 4, 2014	93,309			31.78
	The following table summarizes performance-vested restricted stock and unit activity:
		Performance-			Weighted
		Vested			Average
		Activity			Fair Value
	Nonvested at January 3, 2014	779,678			$	16.41
	Granted	184,578			31.28
	Vested	(221,470	)		18.51
	Forfeited	(5,204	)		15.3
	Nonvested at April 4, 2014	737,582			19.51

Other_Operating_Income_Expense

Other Operating (Income) Expenses, Net	3 Months Ended
	Apr. 04, 2014
Other Income and Expenses [Abstract]	'
OTHER OPERATING (INCOME) EXPENSES, NET	'
	OTHER OPERATING (INCOME) EXPENSES, NET
	Other Operating (Income) Expenses, Net is comprised of the following (in thousands):
		Three Months Ended
		4-Apr-14			29-Mar-13
	2013 operating unit realignment	$	1,003		$	—
	Orthopaedic facility optimization (income) costs	(1,157		)	2,636
	Medical device facility optimization	11			105
	ERP system upgrade (income) costs	(72		)	321
	Acquisition and integration (income) costs	(428		)	111
	Asset dispositions, severance and other	429			65
		$	(214	)	$	3,238
	2013 operating unit realignment. In June 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its former Implantable Medical and Electrochem Solutions (“Electrochem”) reportable segments were combined into one sales and marketing and one operations group serving the entire Company. This initiative is expected to be completed during the first half of 2014. Total restructuring charges expected to be incurred in connection with this realignment are between $7.0 million and $7.5 million, of which $6.6 million has been incurred to date. Expenses related to this initiative will be recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
	•	Severance and retention: $5.3 million – $5.4 million; and
	•	Other: $1.7 million – $2.1 million.
	Other costs primarily consist of relocation, recruitment and travel expenditures.
	The change in accrued liabilities related to the 2013 operating unit realignment is as follows (in thousands):
		Severance and			Other			Total
		Retention
	At January 3, 2014	$	465		$	746		$	1,211
	Restructuring charges	867			136			1,003
	Cash payments	(938		)	(803		)	(1,741		)
	At April 4, 2014	$	394		$	79		$	473
	Orthopaedic facility optimization. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011.
	In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012.
	During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. In connection with this consolidation, in 2012, the Company entered into an agreement to sell assets related to certain non-core Swiss orthopaedic product lines to an independent third party including inventory, machinery, equipment, customer lists and technology related to these product lines. This transaction closed during the first quarter of 2013 and the Company received payments totaling $4.7 million in connection with this transaction and the third party assumed $2.4 million of severance liabilities. During the first quarter of 2014, the Company received an additional contingent payment of $2.5 million from the third party in connection with the achievement of certain milestones defined in the sales agreement. The gain was recognized in Other Operating (Income) Expenses, Net in the Condensed Consolidated Statement of Operations.
	During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next three years.
	The total capital investment expected for these initiatives is between $30 million and $35 million, of which $22.3 million has been expended to date. Total expense expected to be incurred for these initiatives is between $43 million and $48 million, of which $40.0 million has been incurred to date. All expenses will be recorded within the Greatbatch Medical segment and are expected to include the following:
	•	Severance and retention: approximately $11 million;
	•	Accelerated depreciation and asset write-offs: approximately $13 million; and
	•	Other: $19 million – $24 million.
	Other costs include production inefficiencies, moving, revalidation, personnel, training and travel costs associated with these consolidation projects.
	All expenses are cash expenditures, except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands):
		Severance			Accelerated			Other			Total
		and			Depreciation/Asset
		Retention			Write-offs
	At January 3, 2014	$	—		$	—		$	857		$	857
	Restructuring charges (income)	—			(2,531		)	1,374			(1,157		)
	Cash (payments) receipts	—			2,531			(1,423		)	1,108
	At April 4, 2014	$	—		$	—		$	808		$	808
	Medical device facility optimization. Near the end of 2011, the Company initiated plans to upgrade and expand its manufacturing infrastructure in order to support its medical device strategy. This includes the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives are expected to be completed over the next year. Total capital investment under these initiatives is expected to be between $15 million and $20 million, of which approximately $12.5 million has been expended to date. Total expenses expected to be incurred on these projects is between $2.0 million and $3.0 million, of which $1.8 million has been incurred to date. All expenses will be recorded within the Greatbatch Medical segment and are expected to include the following:
	•	Production inefficiencies, moving and revalidation: $0.5 million – $1.0 million;
	•	Personnel: $1.0 million – $1.5 million; and
	•	Other: approximately $1.0 million.
	The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands):
		Production			Personnel			Other			Total
		Inefficiencies,
		Moving and
		Revalidation
	At January 3, 2014	$	—		$	—		$	—		$	—
	Restructuring charges	—			1			10			11
	Cash payments	—			(1		)	(10		)	(11		)
	At April 4, 2014	$	—		$	—		$	—		$	—
	ERP system upgrade. In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative is expected to be completed over the next three months. Total capital investment under this initiative is expected to be between $4.0 million to $4.3 million of which approximately $4.0 million has been expended to date. Total expenses expected to be incurred on this initiative is between $6.0 million to $6.5 million, of which $5.8 million has been incurred to date. Expenses related to this initiative are recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following:
	•	Training and consulting costs: $4 million; and
	•	Accelerated depreciation and asset write-offs: $2 million – $2.5 million.
	The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands):
		Training &			Accelerated			Total
		Consulting			Depreciation/Asset
		Costs			Write-offs
	At January 3, 2014	$	—		$	—		$	—
	Income	(72		)	—			(72		)
	Cash receipts	72			—			72
	At April 4, 2014	$	—		$	—		$	—
Acquisition and integration (income) costs. During 2014 and 2013, the Company incurred (income) cost related to the integration of Micro Power Electronics, Inc. and NeuroNexus Technologies, Inc., which were acquired in December 2011 and February 2012, respectively. These expenses were primarily for retention bonuses, travel costs in connection with integration efforts, training, severance, and the change in fair value of the contingent consideration recorded in connection with these acquisitions. Refer to Note 13 "Fair Value Measurements" for discussion on changes in fair value of the contingent consideration.
Asset dispositions, severance and other. During 2014 and 2013, the Company recorded charges in connection with various other strategic initiatives and asset disposals/write-downs.

Income_Taxes

Income Taxes	3 Months Ended
	Apr. 04, 2014
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	INCOME TAXES
	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
	As of April 4, 2014, the balance of unrecognized tax benefits is approximately $1.9 million. It is reasonably possible that a reduction of up to $0.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $1.7 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments_And_Contingencies

Commitments And Contingencies	3 Months Ended
	Apr. 04, 2014
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	COMMITMENTS AND CONTINGENCIES
	Litigation – On December 21, 2012, the Company and several other unaffiliated parties were named as defendants in a personal injury and wrongful death action filed in the 113th Judicial District Court of Harris County, Texas. The complaint seeks damages alleging marketing and product defects and failure to warn, negligence and gross negligence relating to a product the Company manufactured and sold to a customer, one of the other named defendants. The Company's customer, in turn, incorporated the Greatbatch product into its own product which it sold to its customer, another named defendant. This matter is currently scheduled for trial in the second half of 2014.
	The Company is indemnified by its customer against any loss in this matter, including costs of defense, which obligation is supported by the customer's product liability insurance coverage in the amount of $5 million. The Company also has its own product liability insurance coverage, which has a $10 million retention. The Company has meritorious defenses and is vigorously defending the matter. In the event of an adverse judgment, however, the Company could have liability to the extent of the amount of any award its customer is unable to satisfy. To date, the Company has not recorded a reserve in connection with this matter since any potential loss is not currently probable and the range of loss is not reasonably estimable at this time.
	The Company is a party to various other legal actions arising in the normal course of business. While the Company does not expect that the ultimate resolution of any of these pending actions will have a material effect on its consolidated results of operations, financial position, or cash flows, litigation is subject to inherent uncertainties and there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, does not become material in the future.
	Product Warranties– The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The change in aggregate product warranty liability is as follows (in thousands):
	At January 3, 2014	$	1,819
	Reduction to warranty reserve	(568		)
	Warranty claims paid	(79		)
	At April 4, 2014	$	1,172
	Purchase Commitments – Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable without penalty. As of April 4, 2014, the total contractual obligation related to such expenditures is approximately $28.7 million and will primarily be funded by existing cash and cash equivalents, cash flow from operations, or borrowings under the Credit Facility. The Company also enters into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty.
	Workers’ Compensation Trust - The Company was a member of a group self-insurance trust that provided workers’ compensation benefits to employees of the Company in Western New York (the “Trust”). Under the Trust agreement, each participating organization has joint and several liability for Trust obligations if the assets of the Trust are not sufficient to cover those obligations. During 2011, the Company was notified by the Trust of its intentions to cease operations at the end of 2011 and was assessed a pro-rata share of future costs related to the Trust. Based on actual experience, the Company could receive a refund or be assessed additional contributions for workers’ compensation claims. Since 2011, the Company utilized a traditional insurance provider for workers’ compensation coverage.
	Operating Leases – The Company is a party to various operating lease agreements for buildings, equipment and software. Estimated future operating lease expense is as follows (in thousands):
	Remainder of 2014	$	3,965
	2015	4,742
	2016	4,143
	2017	1,480
	2018	1,003
	Thereafter	936
	Total estimated operating lease expense	$	16,269
	Foreign Currency Contracts – The Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with the operations at its Tijuana, Mexico facility. The impact to the Company’s results of operations from these forward contracts was as follows (in thousands):
		Three Months Ended
		4-Apr-14				29-Mar-13
	Reduction in cost of sales	$	(164	)		$	(172	)
	Ineffective portion of change in fair value	—				—
	Instrument		Type of		Aggregate				Start	End	$/Peso	Fair			Balance Sheet Location
			Hedge		Notional				Date	Date		Value
					Amount
	FX Contract		Cash flow		$	5,781			14-Jan	14-Dec	0.0767	$	(61	)	Accrued Expenses
	FX Contract		Cash flow		$	4,740			14-Jan	14-Dec	0.0752	$	41		Accrued Expenses
	Self-Insured Medical Plan – The Company self-funds the medical insurance coverage provided to its U.S. based employees. The risk to the Company is being limited through the use of stop loss insurance, which has specific stop loss coverage per associate for claims in the year exceeding $225 thousand per associate with no annual maximum aggregate stop loss coverage. As of April 4, 2014, the Company has $1.4 million accrued related to the self-insurance portion of its medical plan, which is recorded in Accrued Expenses in the Condensed Consolidated Balance Sheet, and is primarily based upon claim history.

Earnings_Per_Share_EPS

Earnings Per Share (EPS)	3 Months Ended
	Apr. 04, 2014
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE (EPS)	'
	EARNINGS PER SHARE (“EPS”)
	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
		Three Months Ended
		4-Apr-14			29-Mar-13
	Numerator for basic and diluted EPS:
	Net income	$	14,922		$	5,663
	Denominator for basic EPS:
	Weighted average shares outstanding	24,614			23,750
	Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,080			665
	Denominator for diluted EPS	25,694			24,415
	Basic EPS	$	0.61		$	0.24
	Diluted EPS	$	0.58		$	0.23
	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
		Three Months Ended
		4-Apr-14		29-Mar-13
	Time-vested stock options, restricted stock and restricted stock units	193,000		532,000
	Performance-vested restricted stock units	5,900		595,000
	For the 2013 period, no shares related to CSN were included in the diluted EPS calculations as the average share price of the Company’s common stock for that period did not exceed CSN’s conversion price per share.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	3 Months Ended
	Apr. 04, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE INCOME	'
	ACCUMULATED OTHER COMPREHENSIVE INCOME
	Accumulated Other Comprehensive Income is comprised of the following (in thousands):
	Three Month Period	Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
	Unrealized gain on cash flow hedges	—			150			—			150			(53		)	97
	Realized gain on foreign currency hedges	—			(164		)	—			(164		)	57			(107		)
	Realized loss on interest rate swap hedges	—			132			—			132			(45		)	87
	Foreign currency translation gain	—			—			1,182			1,182			—			1,182
	At April 4, 2014	$	(672	)	$	(350	)	$	16,134		$	15,112		$	505		$	15,617
	Three Month Period	Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At December 28, 2012	$	(962	)	$	120		$	13,431		$	12,589		$	358		$	12,947
	Unrealized gain on cash flow hedges	—			528			—			528			(184		)	344
	Realized gain on foreign currency hedges	—			(172		)	—			(172		)	60			(112		)
	Realized loss on interest rate swap hedges	—			57			—			57			(20		)	37
	Net defined benefit plan gain	597			—			—			597			—			597
	Foreign currency translation loss	—			—			(3,063		)	(3,063		)	—			(3,063		)
	At March 29, 2013	$	(365	)	$	533		$	10,368		$	10,536		$	214		$	10,750
	The realized (gains) losses relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, respectively, in the Condensed Consolidated Statements of Operations.
	The net defined benefit plan reclassifications from Accumulated Other Comprehensive Income are as follows (in thousands):
		Three Months Ended
		29-Mar-13
	Net gain occurring during the period	$	(171	)
	Amortization of losses	(581		)
	Prior service cost	155
	Pre-tax adjustment	(597		)
	Taxes	—
	Net gain	$	(597	)

Fair_Value_Measurements

Fair Value Measurements

3 Months Ended

Apr. 04, 2014

Fair Value Disclosures [Abstract]

'

FAIR VALUE MEASUREMENTS

'

FAIR VALUE MEASUREMENTS

Assets and Liabilities Measured at Fair Value on a Recurring Basis

Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and accrued contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis.

Foreign currency contracts – The fair value of foreign currency contracts are determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs include foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparty to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as additional Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $0.02 million is expected to be realized within the next nine months.

Interest rate swap – The fair value of the Company’s interest rate swap outstanding at April 4, 2014 was determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swap counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s interest rate swap will be realized as Interest Expense as interest on the Credit Facility is accrued.

Accrued contingent consideration – In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through Other Operating (Income) Expenses, Net. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable milestones.

The fair value of accrued contingent consideration recorded by the Company represents the estimated fair value of the contingent consideration the Company expects to pay to the former shareholders of NeuroNexus Technologies, Inc. acquired in 2012 based upon the achievement of certain financial and development-based milestones. The fair value of the contingent consideration liability was estimated by discounting to present value, the probability weighted contingent payments expected to be made utilizing a risk adjusted discount rate. During the first quarter of 2014, the financial milestone expired unachieved and as a result, was determined to have a fair value of zero. The maximum amount of future contingent consideration (undiscounted) that the Company could be required to pay for the development milestone is $1.0 million. The Company’s accrued contingent consideration is categorized in Level 3 of the fair value hierarchy.

Changes in accrued contingent consideration were as follows (in thousands):

At January 3, 2014

$

840

Fair value adjustments

(430

)

At April 4, 2014

$

410

The recurring Level 3 fair value measurements of the Company’s contingent consideration liability include the following significant unobservable inputs (dollars in thousands):

Contingent Consideration Liability

Fair Value at April 4, 2014

Valuation Technique

Unobservable Inputs

Development milestone

$

410

Discounted cash flow

Discount rate

20

%

Projected year of payment

2015

Probability weighted payment amount

$

500

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheet (in thousands):

Fair Value Measurements Using

At

Quoted

Significant

Significant

April 4,

Prices in

Other

Unobservable

Active Markets

Observable

Inputs

for Identical

Inputs

Assets

Description

2014

(Level 1)

(Level 2)

(Level 3)

Liabilities

Interest rate swap (Note 5)

$

330

$

—

$

330

$

—

Foreign currency contracts (Note 10)

20

—

20

—

Accrued contingent consideration

410

—

—

410

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Fair value standards also apply to certain nonfinancial assets and liabilities that are measured at fair value on a nonrecurring basis. As of April 4, 2014 the fair value of the Company’s variable rate Long-Term Debt approximates its carrying value. A summary of the valuation methodologies for the Company’s assets and liabilities measured on a nonrecurring basis is as follows:

Long-lived assets – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that it is more likely than not the long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.

If an indicator is present, potential recoverability is measured by comparing the carrying amount of the long-lived asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value, which is determined by using independent appraisals or discounted cash flow models. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, terminal values, operating budgets, long-term strategic plans and remaining useful lives of the asset or asset group. If the carrying value of the long-lived asset or asset group exceeds the fair value, the carrying value is written down to the fair value in the period identified. The Company did not record any impairment charge related to its long-lived assets during the first three months of 2014 and 2013.

Goodwill and indefinite-lived intangible assets – The Company assesses the impairment of goodwill and other indefinite-lived intangible assets on the last day of each fiscal year, or more frequently if certain indicators are present as described above under long-lived assets. The Company assesses goodwill for impairment by comparing the fair value of its reporting units to their carrying amounts. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Fair values for reporting units are determined based on discounted cash flow models and market multiples. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, terminal values, probability of success factor, operating budgets, and long-term strategic plans. The fair value from the discounted cash flow model is then combined, based on certain weightings, with market multiples in order to determine the fair value of the reporting unit. These market multiples include revenue multiples and multiples of earnings before interest, taxes, depreciation and amortization.

Indefinite-lived intangible assets are assessed for impairment by comparing the fair value of the intangible asset to its carrying value. If the carrying value of the indefinite-lived intangible asset exceeds the fair value, the carrying value is written down to the fair value in the period identified. The fair value of indefinite-lived intangible assets is determined by using a discounted cash flow model. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, royalty rates, operating budgets, and long-term strategic plans.

The Company recorded no impairment charges related to its indefinite-lived intangible assets, including goodwill, during the first three months of 2014 and 2013, respectively. See Note 4 “Intangible Assets” for additional information on the Company’s intangible assets.

Cost and equity method investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments and are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other (Income) Expense, Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at April 4, 2014 and January 3, 2014 was $13.2 million and $12.3 million, respectively. The Company recorded net income (loss) related to its cost and equity method investments of $0.8 million and ($0.07) million during the first three months of 2014 and 2013, respectively.

Business_Segment_Geographic_an

Business Segment, Geographic and Concentration Risk Information	3 Months Ended
	Apr. 04, 2014
Segment Reporting [Abstract]	'
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION	'
	BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION
	In connection with the realignment of the Company's operating structure in 2013 to optimize profitable growth, which included changing the Company's management and reporting structure, the Company reevaluated its operating and reporting segments. Beginning in the fourth quarter of 2013, the Company determined that it has two reportable segments: Greatbatch Medical and QiG Group (“QiG”). As required, the Company reclassified certain prior year amounts to conform them to the current year presentation, including goodwill, segment operating income (loss), and segment sales categorizations.
	Greatbatch Medical designs and manufactures medical devices and components where Greatbatch either owns the intellectual property or has unique manufacturing and assembly expertise and includes the financial results of the former Implantable Medical and Electrochem segments, excluding QiG. Greatbatch Medical provides medical devices and components to the following markets:
	•	Cardiac/Neuromodulation: Products include batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices.
	•	Orthopaedic: Products include hip and shoulder joint reconstruction implants, bone plates and spinal devices, and instruments and delivery systems used in hip and knee replacement, trauma fixation, and spinal surgeries.
	•	Portable Medical: Products include life-saving and life-enhancing applications comprising automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools.
	•	Vascular: Products include introducers, medical coatings, steerable sheaths, and catheters that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery.
	•	Energy, Military, and Environmental (“EME”): Products include primary and rechargeable batteries and battery packs for demanding applications such as down hole drilling tools.
	Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products.
	QiG focuses on developing medical device systems for some of healthcare’s most pressing challenges and reflects Greatbatch’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a disciplined and diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with OEM customers, and strategic equity positions in start-up companies. The development of new medical device systems are facilitated through the establishment of newly formed business entities, usually limited liability companies (“LLC”). These entities do not own, but have the exclusive right to use the technology of Greatbatch Medical in certain, specifically designated fields of use and have an exclusive manufacturing agreement with Greatbatch Medical. QiG currently owns 89% - 100% of three LLCs. Minority interest in these LLCs was granted to key opinion leaders, clinicians and strategic partners. Under the agreements governing these LLCs, QiG is liable for 100% of the expenses incurred by the LLC. However, no distributions are made to the minority holders of the LLC until QiG is reimbursed for all expenses paid. Once QiG has been fully reimbursed, future net income is distributed based upon the respective LLCs ownership percentages. One of the LLCs established by QiG is for the Company's spinal cord stimulator to treat chronic intractable pain of the trunk and/or limbs. This product was submitted for premarket approval (“PMA”) to the United States Food & Drug Administration (“FDA”) in December 2013, and in January 2014 documentation for European CE Mark was submitted to the notified body, TÜV SÜD America. Another medical device system being developed by QiG is an implantable loop recorder for cardiac arrhythmia diagnostics.
	Current QiG revenue includes sales of neural interface technology, components and systems to the neuroscience and clinical markets. Future income of QiG is expected to come from various sources including investment gains from the sales of LLC ownership interests, technology licensing fees, royalty revenue, and/or the sales of medical device systems to OEM customers.
	Historical results reflecting the new business segments for previously reported periods are shown below. An analysis and reconciliation of the Company’s business segment, product line and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped to (in thousands):
		Three Months Ended
		4-Apr-14				29-Mar-13
	Sales:
	Greatbatch Medical
	Cardiac/Neuromodulation	$	86,780			$	70,524
	Orthopaedic	36,431				29,623
	Portable Medical	19,203				18,889
	Vascular	13,050				10,624
	Energy, Military, Environmental	18,131				17,962
	Total Greatbatch Medical	173,595				147,622
	QiG	686				643
	Total sales	$	174,281			$	148,265
		Three Months Ended
		4-Apr-14				29-Mar-13
	Segment income (loss) from operations:
	Greatbatch Medical	$	35,128			$	26,515
	QiG	(5,913		)		(7,356		)
	Total segment income from operations	29,215				19,159
	Unallocated operating expenses	(6,691		)		(4,820		)
	Operating income as reported	22,524				14,339
	Unallocated other expense	(463		)		(7,273		)
	Income before provision for income taxes	$	22,061			$	7,066
		Three Months Ended
		4-Apr-14				29-Mar-13
	Sales by geographic area:
	United States	$	81,112			$	71,334
	Non-Domestic locations:
	Puerto Rico	34,598				28,498
	Belgium	15,979				17,671
	Rest of world	42,592				30,762
	Total sales	$	174,281			$	148,265
	Three customers accounted for a significant portion of the Company’s sales as follows:
		Three Months Ended
		4-Apr-14			29-Mar-13
	Customer A	21	%		19	%
	Customer B	15	%		18	%
	Customer C	12	%		15	%
	Total	48	%		52	%
	Long-lived tangible assets by geographic area are as follows (in thousands):
		As of
		4-Apr-14				3-Jan-14
	United States	$	115,535			$	116,484
	Rest of world	29,651				29,289
	Total	$	145,186			$	145,773

Impact_of_Recently_Issued_Acco

Impact of Recently Issued Accounting Standards	3 Months Ended
	Apr. 04, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS	'
	IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS
	In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission, Emerging Issues Task Force, American Institute of Certified Public Accountants or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements.
	In April 2014, the FASB issued Accounting Standards Update (“ASU”) Update No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” which amends the definition of a discontinued operation and requires entities to provide additional disclosures about disposal transactions that do not meet the discontinued operations criteria. The revised guidance changes how entities identify and disclose information about disposal transactions under U.S. GAAP. The ASU is effective prospectively for all disposals (except disposals classified as held for sale before the adoption date) or components initially classified as held for sale in periods beginning on or after December 15, 2014, with early adoption permitted. The ASU will be applicable for disposal transactions, if any, that the Company enters into after the adoption date.
	In July 2013, the FASB issued ASU No. 2013-11, “Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists.” This ASU requires that entities present an unrecognized tax benefit, or portion of an unrecognized tax benefit, as a reduction to a deferred tax asset in the financial statements for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, with certain exceptions. This ASU was adopted during the first quarter of 2014 and did not impact the Company's Condensed Consolidated Financial Statements as the Company does not have any net operating loss carryforward deferred tax assets that are eligible to be reduced by an unrecognized tax benefit as required by the ASU.

Accounting_Policies_Policies

Accounting Policies (Policies)	3 Months Ended
	Apr. 04, 2014
Accounting Policies [Abstract]	'
Interim Basis of Accounting	'
	The January 3, 2014 condensed consolidated balance sheet data was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 3, 2014.
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Greatbatch, Inc. and its wholly-owned subsidiary, Greatbatch Ltd. (collectively “Greatbatch” or the “Company”), for the periods presented.
Use of Estimates, Policy	'
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period, Policy	'
	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31st. The first quarter of 2014 and 2013 each contained 13 weeks, and ended on April 4, and March 29, respectively.
Income Tax, Policy	'
	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Contingent Liability Reserve Estimate, Policy	'
	In circumstances where an acquisition involves a contingent consideration arrangement, the Company recognizes a liability equal to the fair value of the contingent payments it expects to make as of the acquisition date. The Company re-measures this liability each reporting period and records changes in the fair value through Other Operating (Income) Expenses, Net. Increases or decreases in the fair value of the contingent consideration liability can result from changes in discount periods and rates, as well as changes in the timing, amount of, or the likelihood of achieving the applicable milestones.
Long Lived Assets Finite Lived Intangible Assets	'
	The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that it is more likely than not the long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent.
	If an indicator is present, potential recoverability is measured by comparing the carrying amount of the long-lived asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value, which is determined by using independent appraisals or discounted cash flow models. The discounted cash flow model requires inputs such as a risk-adjusted discount rate, terminal values, operating budgets, long-term strategic plans and remaining useful lives of the asset or asset group. If the carrying value of the long-lived asset or asset group exceeds the fair value, the carrying value is written down to the fair value in the period identified.
Goodwill and Intangible Assets, Goodwill, Policy	'
	The Company assesses the impairment of goodwill and other indefinite-lived intangible assets on the last day of each fiscal year, or more frequently if certain indicators are present as described above under long-lived assets. The Company assesses goodwill for impairment by comparing the fair value of its reporting units to their carrying amounts. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy	'
	Indefinite-lived intangible assets are assessed for impairment by comparing the fair value of the intangible asset to its carrying value. If the carrying value of the indefinite-lived intangible asset exceeds the fair value, the carrying value is written down to the fair value in the period identified.
Cost And Equity Method Investments Policy	'
	The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments and are classified as Other Assets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other (Income) Expense, Net, unless separately stated.

Supplemental_Cash_Flow_Informa1

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Apr. 04, 2014
Supplemental Cash Flow Information [Abstract]	'
Schedule of Cash Flow, Supplemental Disclosures	'
		Three Months Ended
	(in thousands)	April 4, 2014		March 29, 2013
	Noncash investing and financing activities:
	Common stock contributed to 401(k) Plan	$	4,341	$	2,477
	Property, plant and equipment purchases included in accounts payable	1,180		1,219
	Cash paid during the period for:
	Interest	$	953	$	1,556
	Income taxes	544		494

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Apr. 04, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current	'
	Inventories are comprised of the following (in thousands):
		As of
		4-Apr-14		3-Jan-14
	Raw materials	$	66,539	$	67,939
	Work-in-process	36,779		36,670
	Finished goods	14,765		13,749
	Total	$	118,083	$	118,358

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Apr. 04, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets by Major Class	'
	Amortizing intangible assets are comprised of the following (in thousands):
		Gross		Accumulated			Foreign		Net
		Carrying		Amortization			Currency		Carrying
		Amount					Translation		Amount
	At April 4, 2014
	Technology and patents	$	97,376	$	(70,708	)	$	1,993	$	28,661
	Customer lists	68,257		(26,337		)	1,552		43,472
	Other	4,434		(4,532		)	887		789
	Total amortizing intangible assets	$	170,067	$	(101,577	)	$	4,432	$	72,922
	At January 3, 2014
	Technology and patents	$	97,376	$	(69,026	)	$	1,980	$	30,330
	Customer lists	68,257		(24,671		)	1,367		44,953
	Other	4,434		(4,399		)	804		839
	Total amortizing intangible assets	$	170,067	$	(98,096	)	$	4,151	$	76,122
Schedule of Finite-Lived Intangible Assets, Amortization Expense	'
	Aggregate intangible asset amortization expense is comprised of the following (in thousands):
		Three Months Ended
		4-Apr-14		29-Mar-13
	Cost of sales	$	1,563	$	1,780
	Selling, general and administrative expenses	1,717		1,452
	Research, development and engineering costs, net	201		136
	Total intangible asset amortization expense	$	3,481	$	3,368
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	'
	Estimated future intangible asset amortization expense based on the current carrying value is as follows (in thousands):
		Estimated
		Amortization
		Expense
	Remainder of 2014	$	10,238
	2015	12,668
	2016	10,373
	2017	9,251
	2018	6,962
	Thereafter	23,430
	Total estimated amortization expense	$	72,922
Schedule of Intangible Assets Goodwill	'
	Indefinite-lived intangible assets are comprised of the following (in thousands):
		Trademarks
		and
		Tradenames
	At January 3, 2014	$	20,288
	At April 4, 2014	$	20,288
	The change in goodwill is as follows (in thousands):
		Greatbatch Medical		QiG			Total
	At January 3, 2014	$	304,856	$	41,800		$	346,656
	Foreign currency translation	595		—			595
	At April 4, 2014	$	305,451	$	41,800		$	347,251

Debt_Tables

Debt (Tables)	3 Months Ended
	Apr. 04, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt	'
	Long-term debt is comprised of the following (in thousands):
		As of
		4-Apr-14				3-Jan-14
	Revolving line of credit	$	—			$	—
	Variable rate term loan	195,000				197,500
	Total long-term debt	$	195,000			$	197,500
Schedule Of Interest Rate Derivatives	'
	Instrument	Type of		Notional				Start	End	Pay		Current		Fair			Balance
		Hedge		Amount				Date	Date	Fixed		Receive		Value			Sheet Location
										Rate		Floating		April 4, 2014
												Rate
	Interest rate swap	Cash flow		$	100,000			13-Feb	16-Feb	0.573	%	0.157	%	$	(330	)	Other Long-Term Liabilities
Schedule of Interest	'
	The contractual interest and discount amortization for CSN were as follows (in thousands):
		Three months ended
		4-Apr-14				29-Mar-13
	Contractual interest	$	—			$	634
	Discount amortization	—				5,368
Schedule Of Maturities Of Long Term Debt	'
	The expected future minimum principal payments under the Term Loan as of April 4, 2014 are as follows (in thousands):
	Remainder of 2014	$	7,500
	2015	11,250
	2016	16,250
	2017	20,000
	2018	20,000
	Thereafter	120,000
	Total	$	195,000
Schedule of Deferred Financing Costs	'
	The change in deferred financing fees is as follows (in thousands):
	At January 3, 2014	$	3,860
	Amortization during the period	(192		)
	At April 4, 2014	$	3,668

Defined_Benefit_Plans_Tables

Defined Benefit Plans (Tables)	3 Months Ended
	Apr. 04, 2014
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'
Schedule of Defined Benefit Plans Disclosures	'
	The change in net defined benefit plan liability is as follows (in thousands):
	At January 3, 2014	$	1,691
	Net defined benefit cost	77
	Benefit payments	(131		)
	Foreign currency translation	14
	At April 4, 2014	$	1,651
Schedule of Net Benefit Costs	'
	Net defined benefit cost (income) is comprised of the following (in thousands):
		Three Months Ended
		4-Apr-14			29-Mar-13
	Service cost	$	52		$	82
	Interest cost	19			63
	Curtailment gain	—			(1,150		)
	Amortization of net loss	6			—
	Net defined benefit cost (income)	$	77		$	(1,005	)

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Apr. 04, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	'
	The components and classification of stock-based compensation expense were as follows (in thousands):
		Three Months Ended
		4-Apr-14				29-Mar-13
	Stock options	$	604			$	705
	Restricted stock and units	1,557				1,463
	401(k) Plan stock contribution	1,016				263
	Total stock-based compensation expense	$	3,177			$	2,431
	Cost of sales	$	911			$	422
	Selling, general and administrative expenses	1,923				1,867
	Research, development and engineering costs, net	343				142
	Total stock-based compensation expense	$	3,177			$	2,431
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	'
	The weighted average fair value and assumptions used to value options granted are as follows:
		Three Months Ended
		4-Apr-14				29-Mar-13
	Weighted average fair value	$	16.41			$	8.38
	Risk-free interest rate	1.73		%		0.73		%
	Expected volatility	39		%		39		%
	Expected life (in years)	5				5
	Expected dividend yield	—		%		—		%
Schedule of Share-based Compensation, Stock Options, Activity	'
	The following table summarizes time-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Time-Vested			Average				Average	Intrinsic
		Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 3, 2014	1,616,409			$	22.92
	Granted	181,553			43.78
	Exercised	(123,388	)		23.39
	Forfeited or expired	(19,216	)		26.43
	Outstanding at April 4, 2014	1,655,358			25.14				6.7	$	32.6
	Exercisable at April 4, 2014	1,219,492			22.9				5.9	$	26.8
	The following table summarizes performance-vested stock option activity:
		Number of			Weighted				Weighted	Aggregate
		Performance-			Average				Average	Intrinsic
		Vested Stock			Exercise				Remaining	Value
		Options			Price				Contractual	(In Millions)
									Life
									(In Years)
	Outstanding at January 3, 2014	177,261			$	23.27
	Exercised	(24,335	)		22.96
	Outstanding at April 4, 2014	152,926			23.32				3.3	$	3.3
	Exercisable at April 4, 2014	152,926			23.32				3.3	$	3.3
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	'
	The following table summarizes time-vested restricted stock and unit activity:
		Time-Vested			Weighted
		Activity			Average
					Fair Value
	Nonvested at January 3, 2014	67,575			$	26.37
	Granted	34,721			43.99
	Vested	(4,874	)		43.8
	Forfeited	(4,113	)		31.68
	Nonvested at April 4, 2014	93,309			31.78
	The following table summarizes performance-vested restricted stock and unit activity:
		Performance-			Weighted
		Vested			Average
		Activity			Fair Value
	Nonvested at January 3, 2014	779,678			$	16.41
	Granted	184,578			31.28
	Vested	(221,470	)		18.51
	Forfeited	(5,204	)		15.3
	Nonvested at April 4, 2014	737,582			19.51

Other_Operating_Income_Expense1

Other Operating (Income) Expenses, Net (Tables)	3 Months Ended
	Apr. 04, 2014
Other Income and Expenses [Abstract]	'
Schedule Of Other Operating Cost and Expense By Component	'
	Other Operating (Income) Expenses, Net is comprised of the following (in thousands):
		Three Months Ended
		4-Apr-14			29-Mar-13
	2013 operating unit realignment	$	1,003		$	—
	Orthopaedic facility optimization (income) costs	(1,157		)	2,636
	Medical device facility optimization	11			105
	ERP system upgrade (income) costs	(72		)	321
	Acquisition and integration (income) costs	(428		)	111
	Asset dispositions, severance and other	429			65
		$	(214	)	$	3,238
Schedule of Restructuring Reserve by Type of Cost	'
	The change in accrued liabilities related to the medical device facility optimization is as follows (in thousands):
		Production			Personnel			Other			Total
		Inefficiencies,
		Moving and
		Revalidation
	At January 3, 2014	$	—		$	—		$	—		$	—
	Restructuring charges	—			1			10			11
	Cash payments	—			(1		)	(10		)	(11		)
	At April 4, 2014	$	—		$	—		$	—		$	—
	The change in accrued liabilities related to the 2013 operating unit realignment is as follows (in thousands):
		Severance and			Other			Total
		Retention
	At January 3, 2014	$	465		$	746		$	1,211
	Restructuring charges	867			136			1,003
	Cash payments	(938		)	(803		)	(1,741		)
	At April 4, 2014	$	394		$	79		$	473
	The change in accrued liabilities related to the orthopaedic facility optimization is as follows (in thousands):
		Severance			Accelerated			Other			Total
		and			Depreciation/Asset
		Retention			Write-offs
	At January 3, 2014	$	—		$	—		$	857		$	857
	Restructuring charges (income)	—			(2,531		)	1,374			(1,157		)
	Cash (payments) receipts	—			2,531			(1,423		)	1,108
	At April 4, 2014	$	—		$	—		$	808		$	808
	The change in accrued liabilities related to the ERP system upgrade is as follows (in thousands):
		Training &			Accelerated			Total
		Consulting			Depreciation/Asset
		Costs			Write-offs
	At January 3, 2014	$	—		$	—		$	—
	Income	(72		)	—			(72		)
	Cash receipts	72			—			72
	At April 4, 2014	$	—		$	—		$	—

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Apr. 04, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Product Warranty Liability	'
	The change in aggregate product warranty liability is as follows (in thousands):
	At January 3, 2014	$	1,819
	Reduction to warranty reserve	(568		)
	Warranty claims paid	(79		)
	At April 4, 2014	$	1,172
Schedule of Future Minimum Rental Payments for Operating Leases	'
	Estimated future operating lease expense is as follows (in thousands):
	Remainder of 2014	$	3,965
	2015	4,742
	2016	4,143
	2017	1,480
	2018	1,003
	Thereafter	936
	Total estimated operating lease expense	$	16,269
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	'
	The impact to the Company’s results of operations from these forward contracts was as follows (in thousands):
		Three Months Ended
		4-Apr-14				29-Mar-13
	Reduction in cost of sales	$	(164	)		$	(172	)
	Ineffective portion of change in fair value	—				—
Schedule of Foreign Exchange Contracts, Statement of Financial Position	'
	Instrument		Type of		Aggregate				Start	End	$/Peso	Fair			Balance Sheet Location
			Hedge		Notional				Date	Date		Value
					Amount
	FX Contract		Cash flow		$	5,781			14-Jan	14-Dec	0.0767	$	(61	)	Accrued Expenses
	FX Contract		Cash flow		$	4,740			14-Jan	14-Dec	0.0752	$	41		Accrued Expenses

Earnings_Per_Share_EPS_Tables

Earnings Per Share (EPS) (Tables)	3 Months Ended
	Apr. 04, 2014
Earnings Per Share [Abstract]	'
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	'
	The following table illustrates the calculation of Basic and Diluted EPS (in thousands, except per share amounts):
		Three Months Ended
		4-Apr-14			29-Mar-13
	Numerator for basic and diluted EPS:
	Net income	$	14,922		$	5,663
	Denominator for basic EPS:
	Weighted average shares outstanding	24,614			23,750
	Effect of dilutive securities:
	Stock options, restricted stock and restricted stock units	1,080			665
	Denominator for diluted EPS	25,694			24,415
	Basic EPS	$	0.61		$	0.24
	Diluted EPS	$	0.58		$	0.23
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met:
		Three Months Ended
		4-Apr-14		29-Mar-13
	Time-vested stock options, restricted stock and restricted stock units	193,000		532,000
	Performance-vested restricted stock units	5,900		595,000

Comprehensive_Income_Tables

Comprehensive Income (Tables)	3 Months Ended
	Apr. 04, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Schedule of Accumulated Other Comprehensive Income (Loss)	'
	Accumulated Other Comprehensive Income is comprised of the following (in thousands):
	Three Month Period	Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At January 3, 2014	$	(672	)	$	(468	)	$	14,952		$	13,812		$	546		$	14,358
	Unrealized gain on cash flow hedges	—			150			—			150			(53		)	97
	Realized gain on foreign currency hedges	—			(164		)	—			(164		)	57			(107		)
	Realized loss on interest rate swap hedges	—			132			—			132			(45		)	87
	Foreign currency translation gain	—			—			1,182			1,182			—			1,182
	At April 4, 2014	$	(672	)	$	(350	)	$	16,134		$	15,112		$	505		$	15,617
	Three Month Period	Defined			Cash			Foreign			Total			Tax			Net-of-Tax
		Benefit			Flow			Currency			Pre-Tax						Amount
		Plan			Hedges			Translation			Amount
		Liability						Adjustment
	At December 28, 2012	$	(962	)	$	120		$	13,431		$	12,589		$	358		$	12,947
	Unrealized gain on cash flow hedges	—			528			—			528			(184		)	344
	Realized gain on foreign currency hedges	—			(172		)	—			(172		)	60			(112		)
	Realized loss on interest rate swap hedges	—			57			—			57			(20		)	37
	Net defined benefit plan gain	597			—			—			597			—			597
	Foreign currency translation loss	—			—			(3,063		)	(3,063		)	—			(3,063		)
	At March 29, 2013	$	(365	)	$	533		$	10,368		$	10,536		$	214		$	10,750
Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss)	'
		Three Months Ended
		29-Mar-13
	Net gain occurring during the period	$	(171	)
	Amortization of losses	(581		)
	Prior service cost	155
	Pre-tax adjustment	(597		)
	Taxes	—
	Net gain	$	(597	)

Fair_Value_Tables

Fair Value (Tables)

3 Months Ended

Apr. 04, 2014

Fair Value Disclosures [Abstract]

'

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

'

Changes in accrued contingent consideration were as follows (in thousands):

At January 3, 2014

$

840

Fair value adjustments

(430

)

At April 4, 2014

$

410

Fair Value, Measurement Inputs, Disclosure

'

The recurring Level 3 fair value measurements of the Company’s contingent consideration liability include the following significant unobservable inputs (dollars in thousands):

Contingent Consideration Liability

Fair Value at April 4, 2014

Valuation Technique

Unobservable Inputs

Development milestone

$

410

Discounted cash flow

Discount rate

20

%

Projected year of payment

2015

Probability weighted payment amount

$

500

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

'

The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis in the Condensed Consolidated Balance Sheet (in thousands):

Fair Value Measurements Using

At

Quoted

Significant

Significant

April 4,

Prices in

Other

Unobservable

Active Markets

Observable

Inputs

for Identical

Inputs

Assets

Description

2014

(Level 1)

(Level 2)

(Level 3)

Liabilities

Interest rate swap (Note 5)

$

330

$

—

$

330

$

—

Foreign currency contracts (Note 10)

20

—

20

—

Accrued contingent consideration

410

—

—

410

Business_Segment_Geographic_an1

Business Segment, Geographic and Concentration Risk Information (Tables)	3 Months Ended
	Apr. 04, 2014
Segment Reconciliation [Abstract]	'
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	'
		Three Months Ended
		4-Apr-14				29-Mar-13
	Sales:
	Greatbatch Medical
	Cardiac/Neuromodulation	$	86,780			$	70,524
	Orthopaedic	36,431				29,623
	Portable Medical	19,203				18,889
	Vascular	13,050				10,624
	Energy, Military, Environmental	18,131				17,962
	Total Greatbatch Medical	173,595				147,622
	QiG	686				643
	Total sales	$	174,281			$	148,265
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	'
		Three Months Ended
		4-Apr-14				29-Mar-13
	Segment income (loss) from operations:
	Greatbatch Medical	$	35,128			$	26,515
	QiG	(5,913		)		(7,356		)
	Total segment income from operations	29,215				19,159
	Unallocated operating expenses	(6,691		)		(4,820		)
	Operating income as reported	22,524				14,339
	Unallocated other expense	(463		)		(7,273		)
	Income before provision for income taxes	$	22,061			$	7,066
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
	Three customers accounted for a significant portion of the Company’s sales as follows:
		Three Months Ended
		4-Apr-14			29-Mar-13
	Customer A	21	%		19	%
	Customer B	15	%		18	%
	Customer C	12	%		15	%
	Total	48	%		52	%
Geographic Areas, Revenues from External Customers [Abstract]	'
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	'
		Three Months Ended
		4-Apr-14				29-Mar-13
	Sales by geographic area:
	United States	$	81,112			$	71,334
	Non-Domestic locations:
	Puerto Rico	34,598				28,498
	Belgium	15,979				17,671
	Rest of world	42,592				30,762
	Total sales	$	174,281			$	148,265
Geographic Areas, Long-Lived Assets [Abstract]	'
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	'
	Long-lived tangible assets by geographic area are as follows (in thousands):
		As of
		4-Apr-14				3-Jan-14
	United States	$	115,535			$	116,484
	Rest of world	29,651				29,289
	Total	$	145,186			$	145,773

Basis_of_Presentation_Details

Basis of Presentation (Details)	3 Months Ended
	Apr. 04, 2014	Mar. 29, 2013
Accounting Policies [Abstract]	'	'
Weeks In Reporting Period	'13	'13

Supplemental_Cash_Flow_Informa2

Supplemental Cash Flow Information (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]	'	'
Stock Issued During Period, Value, Employee Benefit Plan	$4,341	$2,477
Property, plant and equipment purchases included in accounts payable	1,180	1,219
Interest Paid	953	1,556
Income Taxes Paid	$544	$494

Inventories_Details

Inventories (Details) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Inventory Raw Materials	$66,539	$67,939
Inventory, Work in Process	36,779	36,670
Inventory, Finished Goods	14,765	13,749
Inventories	$118,083	$118,358

Intangible_Assets_Amortizing_I

Intangible Assets (Amortizing Intangible Assets) (Details) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$170,067	$170,067
Finite-Lived Intangible Assets, Accumulated Amortization	-101,577	-98,096
Foreign Currency Translation	4,432	4,151
Amortizing intangible assets, net	72,922	76,122
Purchased Technology And Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	97,376	97,376
Finite-Lived Intangible Assets, Accumulated Amortization	-70,708	-69,026
Foreign Currency Translation	1,993	1,980
Amortizing intangible assets, net	28,661	30,330
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	68,257	68,257
Finite-Lived Intangible Assets, Accumulated Amortization	-26,337	-24,671
Foreign Currency Translation	1,552	1,367
Amortizing intangible assets, net	43,472	44,953
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	4,434	4,434
Finite-Lived Intangible Assets, Accumulated Amortization	-4,532	-4,399
Foreign Currency Translation	887	804
Amortizing intangible assets, net	$789	$839

Intangible_Assets_Amortization

Intangible Assets (Amortization Expense by Categories) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013	Jan. 03, 2014
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite Lived Intangible Assets, Amortization Expense	$3,481	$3,368	'
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]	'	'	'
Remainder of 2014	10,238	'	'
2015	12,668	'	'
2016	10,373	'	'
2017	9,251	'	'
2018	6,962	'	'
Thereafter	23,430	'	'
Amortizing intangible assets, net	72,922	'	76,122
Cost of Sales [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite Lived Intangible Assets, Amortization Expense	1,563	1,780	'
Selling General And Administrative Expense [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite Lived Intangible Assets, Amortization Expense	1,717	1,452	'
Research and Development Expense [Member]	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'
Finite Lived Intangible Assets, Amortization Expense	$201	$136	'

Intangible_Assets_Indefinite_L

Intangible Assets (Indefinite Lived Intangible Assets) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Apr. 04, 2014	Apr. 04, 2014	Apr. 04, 2014	Jan. 03, 2014
		Greatbatch Medical [Member]	QiG [Member]	Trademarks And Tradenames [Member]	Trademarks And Tradenames [Member]
Indefinite-lived Intangible Assets [Roll Forward]	'	'	'	'	'
Indefinite-lived intangible assets, beginning	$20,288	'	'	$20,288	$20,288
Indefinite-lived intangible assets, ending	20,288	'	'	20,288	20,288
Goodwill [Roll Forward]	'	'	'	'	'
Goodwill	346,656	304,856	41,800	'	'
Foreign currency translation	595	595	0	'	'
Goodwill	$347,251	$305,451	$41,800	'	'

Debt_Schedule_of_LongTerm_Debt

Debt (Schedule of Long-Term Debt) (Details) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Line of Credit Facility, Amount Outstanding	$0	$0
Term Loan	195,000	197,500
Long-term debt	$195,000	$197,500

Debt_Credit_Facility_Details_D

Debt (Credit Facility Details) (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Apr. 04, 2014
Line of Credit Facility [Abstract]	'
Credit Facility, Amendment Date	20-Sep-13
Line of Credit Facility, Maximum Borrowing Capacity	$300
Term Loan, Maximum Borrowing Capacity	200
Letter of Credit Subfacility Maximum Borrowing Capacity	15
Swingline Subfacility Maximum Borrowing Capacity	15
Credit Facility Borrowing Capacity Increase	200
Line of Credit Facility, Expiration Date	20-Sep-18
Line Of Credit Expiration Date Extension	20-Sep-19
Debt Instrument, Maturity Date	20-Sep-19
Debt Instrument, Collateral	'The Credit Facility is secured by the Company’s non-realty assets including cash, accounts receivable and inventories.
Interest Margin Above Prime Minimum Credit Facility	0.00%
Interest Margin Above Prime Maximum Credit Facility	0.75%
Interest Margin Above LIBOR Minimum Credit Facility	1.38%
Interest Margin Above LIBOR Maximum Credit Facility	2.75%
Interest Margin Above Prime Minimum Swingline	0.00%
Interest Margin Above Prime Maximum Swingline	0.75%
Line of Credit Facility Commitment Fee Percentage Minimum	0.18%
Line of Credit Facility Commitment Fee Percentage Maximum	0.25%
Credit Facility Aggregate Restricted Activities Limit	300
Credit Facility Maximum Permitted Acquisitions	250
Credit Facility Maximum Other Investment Purchases	100
Credit Facility Maximum Stock Repurchases and Declare Dividends	150
Credit Facility Maximum Foreign Subsidiary Investment	20
Line of Credit, Adjustments to Limitations on Incurrence of Indebtedness, Maximum Leverage Ratio	2.75
Credit Facility Restriction Available	100.00%
Credit Facility Aggregate Restricted Activities Limit Remaining	298
Credit Facility Maximum Other Investment Purchases Remaining	98
Line of Credit Covenant, Adjusted EBITDA to Interest Expense, Ratio Required	3
Line of Credit Covenant, Leverage Ratio, Maximum	4.5
Line of Credit Covenant, Leverage Ratio, Maximum, As of Covenant Restrictive Effective Date	4.25
Total Leverage Covenant Restriction Effective Date	2-Jan-16
Debt Instrument, Covenant Compliance	'As of April 4, 2014, the Company was in compliance with all covenants under the Credit Facility.
Debt Weighted Average Interest Rate	1.57%
Debt Instrument, Unused Borrowing Capacity Amount	$300

Debt_Convertible_Notes_and_Int

Debt (Convertible Notes and Interest Rate Swap Details) (Details) (USD $)	0 Months Ended	3 Months Ended			3 Months Ended
	Feb. 20, 2013	Apr. 04, 2014	Mar. 29, 2013	Mar. 31, 2007	Apr. 04, 2014	Mar. 29, 2013	Dec. 28, 2012	Apr. 04, 2014
					Interest Rate Swap [Member]	Interest Rate Swap [Member]	Interest Rate Swap [Member]	Interest Rate Swap [Member]
								Other Liabilities [Member]
Derivative [Line Items]	'	'	'	'	'	'	'	'
Annual Notional Amortizing Amount	'	'	'	'	$50,000,000	'	'	'
Type of Hedge	'	'	'	'	'Cash flow	'	'	'
Notional Amount	'	'	'	'	100,000,000	'	150,000,000	'
Start Date	'	'	'	'	20-Feb-13	'	'	'
End Date	'	'	'	'	22-Feb-16	'	'	'
Pay Fixed Interest Rate	'	'	'	'	0.57%	'	'	'
Current Receive Variable Interest Rate	'	'	'	'	0.16%	'	'	'
Fair Value	'	'	'	'	'	'	'	-330,000
Description Of Interest Rate Risk Exposure	'	'	'	'	'This swap was entered into in order to hedge against potential changes in cash flows on the outstanding Credit Facility borrowings, which are also indexed to the one-month LIBOR rate.	'	'	'
Description Of Interest Rate Cash Flow Hedge Accounting Method	'	'	'	'	'This swap is being accounted for as a cash flow hedge.	'	'	'
Gain (Loss) Recognized In Income Ineffective Portion	'	'	'	'	0	'	'	'
Interest expense	'	1,084,000	6,988,000	'	100,000	60,000	'	'
Debt Instruments [Abstract]	'	'	'	'	'	'	'	'
Convertible Subordinated Debt	'	'	'	$197,800,000	'	'	'	'
Debt Discount Percentage at Issuance	'	'	'	5.00%	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	'	'	2.25%	'	'	'	'	'
Debt Instrument, Interest Rate During Period	'	'	8.50%	'	'	'	'	'
Debt Redemption Date	20-Feb-13	'	'	'	'	'	'	'

Debt_Contractual_Interest_Deta

Debt (Contractual Interest) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Interest Costs Incurred [Abstract]	'	'
Contractual interest	$0	$634
Discount amortization	$0	$5,368

Debt_Longterm_Debt_Maturity_Sc

Debt (Long-term Debt Maturity Schedule) (Details) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Thousands, unless otherwise specified
Long-term Debt, Fiscal Year Maturity [Abstract]	'	'
Remainder of 2014	$7,500	'
2015	11,250	'
2016	16,250	'
2017	20,000	'
2018	20,000	'
Thereafter	120,000	'
Long-term debt	$195,000	$197,500

Debt_Deferred_Financing_Fees_D

Debt (Deferred Financing Fees) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014
Deferred Finance Costs [Roll Forward]	'
Deferred Finance Costs, Net, Beginning Balance	$3,860
Amortization during the period	-192
Deferred Finance Costs, Net, Ending Balance	$3,668

Defined_Benefit_Plans_Benefit_

Defined Benefit Plans (Benefit Obligation Roll Forward) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]	'	'
Defined Benefit Plan, Benefit Obligation Beginning	$1,691	'
Defined Benefit Plan, Net Periodic Benefit Cost	77	-1,005
Defined Benefit Plan, Benefits Paid	-131	'
Foreign Currency Translation	14	'
Defined Benefit Plan, Benefit Obligation Ending	$1,651	'

Defined_Benefit_Plans_Defined_

Defined Benefit Plans (Defined Benefit Plan Costs) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]	'	'
Service cost	$52	$82
Interest cost	19	63
Curtailment gain	0	-1,150
Amortization of net loss	6	0
Net defined benefit cost (income)	$77	($1,005)

StockBased_Compensation_Expens

Stock-Based Compensation (Expense Details) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	$3,177	$2,431
Stock Option [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	604	705
Restricted Stock And Unit Awards [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	1,557	1,463
Retirement Plan [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	1,016	263
Cost of Sales [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	911	422
Selling General And Administrative Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	1,923	1,867
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	$343	$142

StockBased_Compensation_Fair_V

Stock-Based Compensation (Fair Value Assumptions) (Details) (USD $)	3 Months Ended
	Apr. 04, 2014	Mar. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Weighted average fair value	$16.41	$8.38
Risk-free interest rate	1.73%	0.73%
Expected volatility	39.00%	39.00%
Expected life (in years)	'5 years	'5 years
Expected dividend yield	0.00%	0.00%

StockBased_Compensation_Stock_

Stock-Based Compensation (Stock Option Activity) (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 04, 2014
Stock Options Time Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options Outstanding, Beginning	1,616,409
Option Grants in Period, Gross	181,553
Option Exercises in Period	-123,388
Option Forfeitures and Expirations in Period	-19,216
Stock Options Outstanding, Ending	1,655,358
Options Exercisable, Number	1,219,492
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'
Options Outstanding, Weighted Average Exercise Price, Beginning	$22.92
Option Grants in Period, Weighted Average Exercise Price	$43.78
Option Exercises in Period, Weighted Average Exercise Price	$23.39
Option Forfeitures and Expirations in Period, Weighted Average Exercise Price	$26.43
Options Outstanding, Weighted Average Exercise Price, Ending	$25.14
Options Exercisable, Weighted Average Exercise Price	$22.90
Options Outstanding, Weighted Average Remaining Contractual Term	'6 years 8 months 12 days
Options Exercisable, Weighted Average Remaining Contractual Term	'5 years 10 months 24 days
Options Outstanding, Intrinsic Value	$32.60
Options Exercisable, Intrinsic Value	26.8
Stock Options Performance Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'
Stock Options Outstanding, Beginning	177,261
Option Exercises in Period	-24,335
Stock Options Outstanding, Ending	152,926
Options Exercisable, Number	152,926
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]	'
Options Outstanding, Weighted Average Exercise Price, Beginning	$23.27
Option Exercises in Period, Weighted Average Exercise Price	$22.96
Options Outstanding, Weighted Average Exercise Price, Ending	$23.32
Options Exercisable, Weighted Average Exercise Price	$23.32
Options Outstanding, Weighted Average Remaining Contractual Term	'3 years 3 months 18 days
Options Exercisable, Weighted Average Remaining Contractual Term	'3 years 3 months 18 days
Options Outstanding, Intrinsic Value	3.3
Options Exercisable, Intrinsic Value	$3.30

StockBased_Compensation_Stock_1

Stock-Based Compensation (Stock Award Activity) (Details) (USD $)	3 Months Ended
	Apr. 04, 2014
Restricted Stock And Restricted Stock Units Time Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'
Nonvested Restricted Stock Units and Awards, Beginning	67,575
Restricted Stock Units and Awards Granted	34,721
Restricted Stock Units and Awards Vested	-4,874
Restricted Stock Units and Awards Forfeited	-4,113
Nonvested Restricted Stock Units and Awards, Ending	93,309
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Beginning	$26.37
Restricted Stock Units and Awards Granted, Weighted Average Fair Value	$43.99
Restricted Stock Units and Awards Vested, Weighted Average Fair Value	$43.80
Restricted Stock Units and Awards Forfeited, Weighted Average Fair Value	$31.68
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Ending	$31.78
Restricted Stock And Restricted Stock Units Performance Based [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]	'
Nonvested Restricted Stock Units and Awards, Beginning	779,678
Restricted Stock Units and Awards Granted	184,578
Restricted Stock Units and Awards Vested	-221,470
Restricted Stock Units and Awards Forfeited	-5,204
Nonvested Restricted Stock Units and Awards, Ending	737,582
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]	'
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Beginning	$16.41
Restricted Stock Units and Awards Granted, Weighted Average Fair Value	$31.28
Restricted Stock Units and Awards Vested, Weighted Average Fair Value	$18.51
Restricted Stock Units and Awards Forfeited, Weighted Average Fair Value	$15.30
Restricted Stock Units and Awards, Weighted Average Grant Date Fair Value, Ending	$19.51

Other_Operating_Income_Expense2

Other Operating (Income) Expenses, Net (Expense Categories) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	($214)	$3,238
Operating Unit Realignment [Member]	'	'
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	1,003	0
Orthopaedic Facility Optimization [Member]	'	'
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	-1,157	2,636
Medical Device Facility Optimization [Member]	'	'
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	11	105
ERP System Upgrade [Member]	'	'
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	-72	321
Acquisition And Integration Costs [Member]	'	'
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	-428	111
Asset Dispositions Severance And Other [Member]	'	'
Other Operating Income Expense Detail [Line Items]	'	'
Other Operating (Income) Expenses, Net	$429	$65

Other_Operating_Income_Expense3

Other Operating (Income) Expenses, Net (Restructuring Costs and Reserve Details) (Details) (USD $)

3 Months Ended

12 Months Ended

3 Months Ended

Apr. 04, 2014

Mar. 29, 2013

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Jan. 03, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Apr. 04, 2014

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Operating Unit Realignment [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Orthopaedic Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

Medical Device Facility Optimization [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

ERP System Upgrade [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Severance And Retention [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Other Restructuring [Member]

Minimum [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Training And Consulting Costs [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Severance And Retention [Member]

Other Restructuring [Member]

Severance And Retention [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Other Restructuring [Member]

Production Inefficiencies, Moving And Revalidation [Member]

Personnel [Member]

Production Inefficiencies, Moving And Revalidation [Member]

Personnel [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Accelerated Depreciation And Asset Write Offs [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and Related Activities, Description

'

'

'In June 2013, the Company initiated a plan to realign its operating structure in order to optimize its continued focus on profitable growth. As part of this initiative, the sales and marketing and operations groups of its former Implantable Medical and Electrochem reportable segments were combined into one sales and marketing and one operations group serving the entire Company.

'

'

'

'

'

'

'In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities and reduce dependence on outside suppliers. This initiative was completed in 2011. In 2011, the Company began construction on an orthopaedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012. During 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next three years.

'

'

'

'

'

'

'

'Near the end of 2011, the Company initiated plans to upgrade and expand its manufacturing infrastructure in order to support its medical device strategy. This includes the transfer of certain product lines to create additional capacity for the manufacture of medical devices, expansion of two existing facilities, as well as the purchase of equipment to enable the production of medical devices. These initiatives are expected to be completed over the next year.

'

'

'

'

'

'

'

'In 2011, the Company initiated plans to upgrade its existing global ERP system. This initiative is expected to be completed over the next three months.

'

'

'

'

'

Restructuring Initiation Date

'

'

'June 2013

'

'

'

'

'

'

'2010

'

'

'

'

'

'

'

'2011

'

'

'

'

'

'

'

'2011

'

'

'

'

'

Restructuring And Related Activities Expected Capital Expenditures

'

'

'

'

'

'

'

'

'

'

'

'

'

$30,000,000

'

$35,000,000

'

'

'

$15,000,000

'

'

$20,000,000

'

'

'

'

$4,000,000

'

$4,300,000

'

Restructuring And Related Activities Capital Expenditures Incurred To Date

'

'

'

'

'

'

'

'

'

22,300,000

'

'

'

'

'

'

'

12,500,000

'

'

'

'

'

'

'

4,000,000

'

'

'

'

'

Restructuring and Related Cost, Expected Cost

'

'

'

7,000,000

5,300,000

1,700,000

7,500,000

5,400,000

2,100,000

'

'

11,000,000

13,000,000

43,000,000

19,000,000

48,000,000

24,000,000

'

1,000,000

2,000,000

500,000

1,000,000

3,000,000

1,000,000

1,500,000

'

4,000,000

6,000,000

2,000,000

6,500,000

2,500,000

Restructuring and Related Cost, Cost Incurred to Date

'

'

6,600,000

'

'

'

'

'

'

40,000,000

'

'

'

'

'

'

'

1,800,000

'

'

'

'

'

'

'

5,800,000

'

'

'

'

'

Proceeds from sale of orthopaedic product lines (Note 8)

2,531,000

1,768,000

'

'

'

'

'

'

'

'

4,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liabilities Assumed By Third Parties

'

'

'

'

'

'

'

'

'

'

2,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Gain (Loss) on Disposition of Business

'

'

'

'

'

'

'

'

'

$2,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other_Operating_Income_Expense4

Other Operating (Income) Expenses, Net Changes in Accrued Liabilities (Details) (USD $)	3 Months Ended	12 Months Ended
	Apr. 04, 2014	Jan. 03, 2014
Operating Unit Realignment [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	$1,211,000	'
Restructuring charges	1,003,000	'
Cash (payments) receipts	-1,741,000	'
Restructuring Reserve, Ending Balance	473,000	'
Orthopaedic Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	857,000	'
Restructuring charges	-1,157,000	'
Liability assumed in sale of product lines	'	-2,400,000
Cash (payments) receipts	1,108,000	'
Restructuring Reserve, Ending Balance	808,000	857,000
Medical Device Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	11,000	'
Cash (payments) receipts	-11,000	'
Restructuring Reserve, Ending Balance	0	'
ERP System Upgrade [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	72,000	'
Cash (payments) receipts	72,000	'
Restructuring Reserve, Ending Balance	0	'
Severance And Retention [Member] | Operating Unit Realignment [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	465,000	'
Restructuring charges	867,000	'
Cash (payments) receipts	-938,000	'
Restructuring Reserve, Ending Balance	394,000	'
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	0	'
Cash (payments) receipts	0	'
Restructuring Reserve, Ending Balance	0	'
Production Inefficiencies, Moving And Revalidation [Member] | Medical Device Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	0	'
Cash (payments) receipts	0	'
Restructuring Reserve, Ending Balance	0	'
Training And Consulting Costs [Member] | ERP System Upgrade [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	72,000	'
Cash (payments) receipts	72,000	'
Restructuring Reserve, Ending Balance	0	'
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	-2,531,000	'
Cash (payments) receipts	2,531,000	'
Restructuring Reserve, Ending Balance	0	'
Accelerated Depreciation And Asset Write Offs [Member] | ERP System Upgrade [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	0	'
Cash (payments) receipts	0	'
Restructuring Reserve, Ending Balance	0	'
Personnel [Member] | Medical Device Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	1,000	'
Cash (payments) receipts	-1,000	'
Restructuring Reserve, Ending Balance	0	'
Other Restructuring [Member] | Operating Unit Realignment [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	746,000	'
Restructuring charges	136,000	'
Cash (payments) receipts	-803,000	'
Restructuring Reserve, Ending Balance	79,000	'
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	857,000	'
Restructuring charges	1,374,000	'
Cash (payments) receipts	-1,423,000	'
Restructuring Reserve, Ending Balance	808,000	'
Other Restructuring [Member] | Medical Device Facility Optimization [Member]	'	'
Restructuring Reserve [Roll Forward]	'	'
Restructuring Reserve, Beginning Balance	0	'
Restructuring charges	10,000	'
Cash (payments) receipts	-10,000	'
Restructuring Reserve, Ending Balance	$0	'

Income_Taxes_Narratives_Detail

Income Taxes (Narratives) (Details) (USD $)	Apr. 04, 2014
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'
Unrecognized Tax Benefits	$1.90
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0.1
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$1.70

Commitments_and_Contingencies_1

Commitments and Contingencies (Narratives) (Details) (USD $)	3 Months Ended
	Apr. 04, 2014
Loss Contingencies [Line Items]	'
Standard Product Warranty Description	'The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Significant Purchase Commitment Description	'Contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding on the Company and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. The Company’s purchase orders are normally based on its current manufacturing needs and are fulfilled by its vendors within short time horizons. The Company also enters into blanket orders with vendors that have preferred pricing and terms, however these orders are normally cancelable without penalty.
Significant Purchase Commitment Remaining Minimum Amount Committed	$28,700,000
Description of Types of Foreign Currency Cash Flow Hedging Instruments Used	'The Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with the operations at its Tijuana, Mexico facility.
Maximum Aggregate Loss Under Medical Plan Stop Loss Insurance Per Employee	225,000
Accrued Self Insured Medical Plan Liability	1,400,000
Litigation One [Member]	'
Loss Contingencies [Line Items]	'
Customer Product Liability Insurance Coverage	5,000,000
Loss Contingency Domicile Of Litigation	'113th Judicial District Court of Harris County, Texas
Loss Contingency Allegations	'The complaint seeks damages alleging marketing and product defects and failure to warn, negligence and gross negligence relating to a product the Company manufactured and sold to a customer, one of the other named defendants. The Company's customer, in turn, incorporated the Greatbatch product into its own product which it sold to its customer, another named defendant.
Loss Contingency Opinion Of Counsel	'To date, the Company has not recorded a reserve in connection with this matter since any potential loss is not currently probable and the range of loss is not reasonably estimable at this time.
Product Liability Insurance Coverage	$10,000,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Product Warranty Rollforward) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014
Movement in Standard Product Warranty Accrual [Roll Forward]	'
Standard Product Warranty Accrual, Beginning Balance	$1,819
Standard Product Warranty Accrual, Warranties Issued	-568
Standard Product Warranty Accrual, Payments	-79
Standard Product Warranty Accrual, Ending Balance	$1,172

Commitments_and_Contingencies_3

Commitments and Contingencies (Future Lease Payments) (Details) (USD $)	Apr. 04, 2014
In Thousands, unless otherwise specified
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'
Remainder of 2014	$3,965
2015	4,742
2016	4,143
2017	1,480
2018	1,003
Thereafter	936
Total estimated operating lease expense	$16,269

Commitments_and_Contingencies_4

Commitments and Contingencies (FX Contract Details) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Foreign Currency Cash Flow Hedges [Abstract]	'	'
Increase (reduction) in Cost of Sales	$164	$172
Ineffective portion of change in fair value	0	0
Fx Contract 1 [Member]	'	'
Derivative [Line Items]	'	'
Derivative, Type of Instrument	'FX Contract	'
Notional Amount of Foreign Currency Cash Flow Hedge Derivatives	5,781	'
Start Date	1-Jan-14	'
End Date	31-Dec-14	'
$/Peso	0.0767	'
Fair Value	-61	'
Balance Sheet Location	'Accrued Expenses	'
Fx Contract 2 [Member]	'	'
Derivative [Line Items]	'	'
Derivative, Type of Instrument	'FX Contract	'
Notional Amount of Foreign Currency Cash Flow Hedge Derivatives	4,740	'
Start Date	1-Jan-14	'
End Date	31-Dec-14	'
$/Peso	0.0752	'
Fair Value	$41	'
Balance Sheet Location	'Accrued Expenses	'

Earnings_Per_Share_EPS_Details

Earnings Per Share (EPS) (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]	'	'
Net income	$14,922	$5,663
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]	'	'
Basic	24,614,000	23,750,000
Effect of dilutive securities stock options, restricted stock and restricted stock units	1,080,000	665,000
Denominator for diluted EPS	25,694,000	24,415,000
Basic EPS	$0.61	$0.24
Diluted EPS	$0.58	$0.23
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]	'	'
Time-vested stock options, restricted stock and restricted stock units	193,000	532,000
Performance-vested stock options and restricted stock units	5,900	595,000
Convertible Note Shares Included In Diluted Share Calculation	'	0

Comprehensive_Income_Details

Comprehensive Income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Tax, [Abstract]	'	'
Defined Benefit Plan Liability, Beginning	($672)	($962)
Net defined benefit plan liability adjustments	'	597
Defined Benefit Plan Liability, Ending	-672	-365
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, before Tax [Abstract]	'	'
Cash Flow Hedges, Beginning	-468	120
Unrealized gain (loss) on cash flow hedges	150	528
Realized Gain Loss On Foreign Currency Contracts Before Tax	-164	-172
Realized Gain Loss On Interest Rate Swaps Before Tax	132	57
Cash Flow Hedges, End	-350	533
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax [Abstract]	'	'
Foreign Currency Translation Adjustment, Beginning	14,952	13,431
Net foreign currency translation gain (loss)	1,182	-3,063
Foreign Currency Translation Adjustment, End	16,134	10,368
Other Comprehensive Income (Loss), before Tax [Abstract]	'	'
Total Pre-Tax Amount, Beginning	13,812	12,589
Unrealized gain (loss) on cash flow hedges	150	528
Realized gain loss on foreign currency hedges - before tax	-164	-172
Realized gain loss on interest rate swaps - before tax	132	57
Net defined benefit plan liability adjustments	'	597
Net foreign currency translation gain (loss)	1,182	-3,063
Total Pre-Tax Amount, End	15,112	10,536
Other Comprehensive Income (Loss), Tax [Abstract]	'	'
Tax, Beginning	546	358
Unrealized gain (loss) on cash flow hedges	-53	-184
Realized gain loss on foreign currency contracts - tax	57	60
Realized gain loss on interest rate swap hedges - tax	-45	-20
Net defined benefit plan liability adjustments	'	0
Net foreign currency translation gain (loss)	0	0
Tax, End	505	214
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'
Net-of-Tax Amount, Beginning	14,358	12,947
Unrealized gain (loss) on cash flow hedges, net of tax	97	344
Realized gain loss on foreign currency hedges, net of tax	-107	-112
Realized gain loss on interest rate swap hedges, net of tax	87	37
Net defined benefit plan liability adjustments	0	-597
Foreign currency translation gain (loss)	1,182	-3,063
Net-of-Tax Amount, End	$15,617	$10,750

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income Amounts Recognized in AOCI (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, before Tax	'	($171)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Gain (Loss), before Tax	'	-581
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit) Arising During Period, before Tax	'	155
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	'	-597
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax	'	0
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net Unamortized Gain (Loss) Arising During Period, Net of Tax	$0	($597)

Fair_Value_Measurement_Recurri

Fair Value Measurement (Recurring Measurements) (Details) (USD $)	Apr. 04, 2014
In Millions, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]	'
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$0.02

Fair_Value_Measurement_Conting

Fair Value Measurement (Contingent Consideration Roll Forward) (Details) (USD $)	3 Months Ended
	Apr. 04, 2014
Contingent Consideration Liability [Roll Forward]	'
Accrued Contingent Consideration, Beginning Balance	$840,000
Change in Amount of Contingent Consideration Liability	-430,000
Accrued Contingent Consideration, Ending Balance	410,000
Financial Milestones [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Contingent Consideration Fair Value	$0

Fair_Value_Measurement_Conting1

Fair Value Measurement (Contingent Consideration Assumptions) (Details) (Development Milestones [Member], USD $)	3 Months Ended
	Apr. 04, 2014
Development Milestones [Member]	'
Fair Value Assumptions [Line Items]	'
Contingent Consideration Fair Value	$410,000
Risk Adjusted Discount Rate For Contingent Consideration	20.00%
Contingent Consideration Liability Projected Year Of Payment	'2015
Contingent Consideration Liability Probability Weighted Payment Amount	$500,000

Fair_Value_Measurement_Recurri1

Fair Value Measurement (Recurring and Nonrecurring Measurement Basis) (Details) (USD $)	3 Months Ended
	Apr. 04, 2014	Mar. 29, 2013	Jan. 03, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Interest rate swap	$330,000	'	'
Foreign currency contracts	20,000	'	'
Accrued contingent consideration	410,000	'	840,000
Assets, Fair Value Disclosure [Abstract]	'	'	'
Long Lived Assets Impairment Loss	0	0	'
Maximum Potential Payment Due Upon Achievement Of Certain Milestones	1,000,000	'	'
Goodwill, Impairment Loss	0	0	'
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	'	0	'
Impairment of Intangible Assets (Excluding Goodwill)	0	'	'
Cost And Equity Method Investments Aggregate Carrying Amount	13,200,000	'	12,300,000
Cost And Equity Method Investments Realized Gains Losses Net	800,000	-70,000	'
Fair Value, Inputs, Level 1 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Interest rate swap	0	'	'
Foreign currency contracts	0	'	'
Accrued contingent consideration	0	'	'
Fair Value, Inputs, Level 2 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Interest rate swap	330,000	'	'
Foreign currency contracts	20,000	'	'
Accrued contingent consideration	0	'	'
Fair Value, Inputs, Level 3 [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Interest rate swap	0	'	'
Foreign currency contracts	0	'	'
Accrued contingent consideration	$410,000	'	'

Recovered_Sheet1

Business Segment, Geographic And Concentration Risk Information (Segment Revenue by Categories) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
	Segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]	'	'
Number of Reportable Segments	2	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	$174,281	$148,265
Revenue, Major Customer [Line Items]	'	'
Concentration Risk, Percentage	48.00%	52.00%
Customer A [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Concentration Risk, Percentage	21.00%	19.00%
Customer B [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Concentration Risk, Percentage	15.00%	18.00%
Customer C [Member]	'	'
Revenue, Major Customer [Line Items]	'	'
Concentration Risk, Percentage	12.00%	15.00%
United States [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	81,112	71,334
Puerto Rico [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	34,598	28,498
Belgium [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	15,979	17,671
Rest Of World [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	42,592	30,762
Greatbatch Medical [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	173,595	147,622
Greatbatch Medical [Member] | Cardiac Neuromodulation [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	86,780	70,524
Greatbatch Medical [Member] | Orthopaedic [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	36,431	29,623
Greatbatch Medical [Member] | Portable Medical [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	19,203	18,889
Greatbatch Medical [Member] | Vascular [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	13,050	10,624
Greatbatch Medical [Member] | EME and Other [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Sales Revenue, Net	18,131	17,962
QiG [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Controlling Interest, Number of Ownership Interests	3	'
Controlling Interest, Liability of Expenses Incurred, Percentage	100.00%	'
FDA submission date	16-Dec-13	'
Sales Revenue, Net	$686	$643
CE submission date	10-Jan-14	'
Maximum [Member] | QiG [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Parent	100.00%	'
Minimum [Member] | QiG [Member]	'	'
Segment Reporting, Revenue Reconciling Item [Line Items]	'	'
Noncontrolling Interest, Ownership Percentage by Parent	89.00%	'

Recovered_Sheet2

Business Segment, Geographic And Concentration Risk Information (Segment Income From Operations) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Apr. 04, 2014	Mar. 29, 2013
Segment Reporting Information [Line Items]	'	'
Operating income as reported	$22,524	$14,339
Unallocated Other Expense	-463	-7,273
Income before provision for income taxes	22,061	7,066
QiG [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Operating income as reported	-5,913	-7,356
Greatbatch Medical [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Operating income as reported	35,128	26,515
Operating Segments [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Operating income as reported	29,215	19,159
Segment Reconciling Items [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Operating income as reported	($6,691)	($4,820)

Business_Segment_Geographic_An2

Business Segment, Geographic And Concentration Risk Information (Long-lived Assets by Category) (Details) (USD $)	Apr. 04, 2014	Jan. 03, 2014
In Thousands, unless otherwise specified
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Property, plant and equipment, net	$145,186	$145,773
United States [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Property, plant and equipment, net	115,535	116,484
Rest Of World [Member]	'	'
Segment Reporting, Asset Reconciling Item [Line Items]	'	'
Property, plant and equipment, net	$29,651	$29,289